Long-Term Outcomes of Hypopituitarism Following Gamma Knife Radiosurgery for Pituitary Adenomas
NCT ID: NCT07015645
Last Updated: 2025-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
137 participants
OBSERVATIONAL
2019-01-01
2025-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endocrine Outcome of Surgery for Pituitary Adenoma
NCT03515603
The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor
NCT01377701
Hypofractionated Radiosurgery to Treat Residual/recurrent Non Secreting Pituitary Adenoma (HYPOADENO)
NCT06826170
Gamma Knife Radiosurgery on Tectal Plate Gliomas
NCT07015710
A Twenty-years' Experience in Pituitary Disease.
NCT06973824
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Initial gamma knife radiosurgery (GKRS) can be an alternative treatment for selected NFPA patients with comorbidities, documented growth small tumors, cavernous sinus invasion, or advanced age.
Hypopituitarism is one of the most common complications of radiosurgery (Cordeiro et al., 2018). Long-term follow-up is crucial to assess new pituitary deficits. Typically, hypopituitarism presents within the first 2-4 years after the treatment with radiosurgery, but the risk of pituitary insufficiency increases to up to 80%. Reports on the highest incidence of new-onset hypopituitarism also mentioned the longest follow-up period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pituitary Adenomas group
Patients received gamma knife radiosurgery (GKRS) treatment for pituitary adenomas.
Gamma Knife Radiosurgery
Patients received gamma knife radiosurgery (GKRS) treatment for pituitary adenomas.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gamma Knife Radiosurgery
Patients received gamma knife radiosurgery (GKRS) treatment for pituitary adenomas.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Patients treated with gamma knife radiosurgery (GKRS).
Exclusion Criteria
* Patients who had undergone previous radiation therapy.
* Pituitary insufficiency which presents before gamma knife radiosurgery (GKRS).
* Patients without visible glands.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Al-Azhar University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Awad Mohamed Hegab
Lecturer of Neurosurgery, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al-Azhar University (Damietta)
Damietta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DFM-IRB 00012367-25-05-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.